Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Epilepsia. 2023 May 15;64(7):1821–1832. doi: 10.1111/epi.17630

Figure 3.

Figure 3.

Clinical response to standard first-line treatment for epileptic spasms (ES) in CDKL5 Deficiency Disorder (CDD) and a comparison cohort from the National Infantile Spasms Consortium (NISC) when used as after another treatment and/or beyond one month from ES onset. Standard treatments included hormonal treatments, adrenocorticotropic hormone (ACTH) and oral corticosteroids, and vigabatrin.